<DOC>
	<DOCNO>NCT01224964</DOCNO>
	<brief_summary>The main objective study : 1 . To unravel importance molecular phenotyping predict response classical anti-asthma treatment ( leukotriene antagonist ) The investigator develop non-invasive technique base mRNA analysis induce sputum enables u study airway inflammation detail . This technique form basis current project base follow hypothesis : 1 . Different molecular asthma phenotype exist : Th2 phenotype non Th2 phenotype report Woodruff colleague ( Woodruff PG et al ) . Sputum mRNA cytokine level use diagnose Th2 asthma discriminate non-Th2 asthma . 2 . Based previous research preliminary data non-Th2 asthma divide Th17 asthma Th1+Th2 asthma ; besides , fourth group without Th2 , Th17 Th1 characteristic also exist . 3 . These subgroup different response anti-leukotrienes .</brief_summary>
	<brief_title>Development Validation Sputum Biomarker mRNA Panel Diagnostic Work-up Asthma 3</brief_title>
	<detailed_description />
	<mesh_term>Montelukast</mesh_term>
	<criteria>uncontrolled persistent asthmatic daily inhale corticosteroid ( GINA ) viral/fungal/bacterial infection +fever ( &lt; 1 month ) asthma exacerbation ( &lt; 3 month ) respiratory disease ( CF , ciliary dyskinesia , bronchiectasis ) cardiac patient use betablockers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>